INSP · CIK 1609550
What Inspire Medical Systems, Inc. told the SEC could break it.
Inspire Medical Systems' disclosures point to concentration across its supply chain, facilities, and revenue. It relies on third-party suppliers to make the Inspire system, many of them single- or sole-source for certain materials and components — disruptions it has already experienced and buffers with extra inventory. Its operations are also single-sited: substantially all R&D and back-office work happens at two Golden Valley, Minnesota locations with no redundant facilities, so damage there could halt development and supply. And its revenue depends on third-party reimbursement, with commercial payors covering roughly 45-50% of U.S. Inspire implants and Medicare Advantage another 15-20%, so coverage changes would directly affect demand.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single/sole-source suppliers for Inspire system componentshigh
Inspire relies on third-party suppliers to manufacture the Inspire system and its components, many of which are single-source/sole suppliers for certain materials and components; the company has experienced supply disruptions and holds extra inventory to buffer interruptions.
“We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers.”
SEC filing →As of 2026
Geographic concentration
- single-site R&D (Golden Valley, MN; no redundant facilities)medium
Inspire performs substantially all R&D and back-office activity at two locations in Golden Valley, Minnesota and has no redundant facilities; damage to them could halt research, development and supply of the Inspire system.
“We do not have redundant facilities. We perform substantially all of our research and development and back-office activity at two locations in Golden Valley, Minnesota.”
SEC filing →As of 2026
Regulatory & policy
- third-party reimbursement / payor coverage dependencymedium
Inspire's revenue depends on third-party reimbursement: commercial payors cover ~45-50% of U.S. Inspire implants and Medicare Advantage ~15-20%; changes in coverage or reimbursement policies would directly affect demand.
“Historically, commercial payors cover approximately 45% to 50% of Inspire implants in the U.S. Medicare Advantage, which is also managed by the private commercial health care plans, covers approximately 15% to 20% of Inspire implants.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch